Literature DB >> 26328025

From the stomach to other organs: Helicobacter pylori and the liver.

Marek Waluga1, Michał Kukla1, Michał Żorniak1, Agata Bacik1, Rafał Kotulski1.   

Abstract

Many recent studies have examined the importance of Helicobacter pylori (H. pylori) infection in the pathogenesis of the diseases outside the stomach and explored the significance of this bacterium in the pathogenesis of some metabolic and cardiovascular diseases. Recent studies have provided evidence that H. pylori is also involved in the pathogenesis of some liver diseases. Many observations have proved that H. pylori infection is important in the development of insulin resistance, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver fibrosis and cirrhosis. The worsening of liver inflammation of different origins also occurs during H. pylori infection. Some studies have indicated that H. pylori infection induces autoimmunological diseases in the liver and biliary tract. The potential significance of this bacterium in carcinogenesis is unclear, but it is within the scope of interest of many studies. The proposed mechanisms through which H. pylori impacts the development of hepatobiliary diseases are complex and ambiguous. The importance of other Helicobacter species in the development of hepatobiliary diseases is also considered because they could lead to the development of inflammatory, fibrotic and necrotic injuries of the liver and, consequently, to hepatocellular carcinoma. However, many contrary viewpoints indicate that some evidence is not convincing, and further studies of the subject are needed. This review presents the current knowledge about the importance of H. pylori in the pathogenesis of liver and in biliary diseases.

Entities:  

Keywords:  Helicobacter pylori; Hepatic carcinoma; Liver cirrhosis; Liver fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Year:  2015        PMID: 26328025      PMCID: PMC4550868          DOI: 10.4254/wjh.v7.i18.2136

Source DB:  PubMed          Journal:  World J Hepatol


  126 in total

1.  Helicobacter sp. are not detectable in bile from German patients with biliary disease.

Authors:  J Rudi; A Rudy; M Maiwald; W Stremmel
Journal:  Gastroenterology       Date:  1999-04       Impact factor: 22.682

2.  Role of amplification in phospholipase Cγ2 activation in modulation of gastric mucosal inflammatory responses to Helicobacter pylori: effect of ghrelin.

Authors:  B L Slomiany; A Slomiany
Journal:  Inflammopharmacology       Date:  2014-11-02       Impact factor: 4.473

3.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

4.  Helicobacter pylori infection increases mucosal permeability of the stomach and intestine.

Authors:  Y Fukuda; H Bamba; M Okui; K Tamura; N Tanida; M Satomi; T Shimoyama; T Nishigami
Journal:  Digestion       Date:  2001       Impact factor: 3.216

5.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 6.  Breast cancer: should gastrointestinal bacteria be on our radar screen?

Authors:  Varada P Rao; Theofilos Poutahidis; James G Fox; Susan E Erdman
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Lack of association between seroprevalence of Helicobacter pylori infection and primary biliary cirrhosis.

Authors:  Marilena Durazzo; Floriano Rosina; Alberto Premoli; Enrico Morello; Sharmila Fagoonee; Rosaria Innarella; Enrico Solerio; Rinaldo Pellicano; Mario Rizzetto
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

8.  Expression of hepatitis B virus antigen and Helicobacter pylori infection in gastric mucosa of patients with chronic liver disease.

Authors:  Nai-Ling Chen; Ling Bai; Tao Deng; Chang Zhang; Qing-Yun Kong; Hao Chen
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2004-05

9.  Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates.

Authors:  R Feinstein; H Kanety; M Z Papa; B Lunenfeld; A Karasik
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

10.  Lack of an association between Helicobacter infection and autoimmune hepatitis in children.

Authors:  Katarzyna Dzierzanowska-Fangrat; Ingrid Nilsson; Małgorzata Wozniak; Paulina Jozwiak; Elzbieta Rozynek; Marek Woynarowski; Jerzy Socha; Asa Ljungh; Torkel Wadström
Journal:  Pol J Microbiol       Date:  2006
View more
  21 in total

1.  Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model.

Authors:  Linghua Yu; Linlin Wang; Huixing Yi; Xiaojun Wu
Journal:  Gut Microbes       Date:  2020-03-13

2.  Reply to High hepatocellular carcinoma risk among US-born Hispanics.

Authors:  V Wendy Setiawan; Pengxiao C Wei; Brenda Y Hernandez; Shelly C Lu; Kristine R Monroe; Loic Le Marchand; Jian Min Yuan
Journal:  Cancer       Date:  2016-10-14       Impact factor: 6.860

Review 3.  Co-infections with liver fluke and Helicobacter species: A paradigm change in pathogenesis of opisthorchiasis and cholangiocarcinoma?

Authors:  Banchob Sripa; Raksawan Deenonpoe; Paul J Brindley
Journal:  Parasitol Int       Date:  2016-12-03       Impact factor: 2.230

4.  Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection.

Authors:  Chang-Hai Liu; Wei Jiang; Dong-Bo Wu; Qing-Min Zeng; You-Juan Wang; Hong Tang
Journal:  Dig Dis Sci       Date:  2022-10-13       Impact factor: 3.487

5.  The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori.

Authors:  Albert Lecube; Silvia Valladares; Carolina López-Cano; Liliana Gutiérrez; Andreea Ciudin; José Manuel Fort; Josep Maria Reñé; Xavier Matias-Guiu; Inés de Torres; Marta Bueno; Judit Pallarés; Juan Antonio Baena
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

6.  Helicobacter pylori infection among patients with liver cirrhosis.

Authors:  Joanna Pogorzelska; Magda Łapińska; Alicja Kalinowska; Tadeusz W Łapiński; Robert Flisiak
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-10       Impact factor: 2.566

7.  Evaluation of Helicobacter pylori Infection in Patients with Chronic Hepatic Disease.

Authors:  Ju Huang; Jun Cui
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

8.  Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala.

Authors:  Christian S Alvarez; Andrea A Florio; Julia Butt; Alvaro Rivera-Andrade; María F Kroker-Lobos; Tim Waterboer; Maria Constanza Camargo; Neal D Freedman; Barry I Graubard; Mariana Lazo; Eliseo Guallar; John D Groopman; Manuel Ramírez-Zea; Katherine A McGlynn
Journal:  Helicobacter       Date:  2020-10-02       Impact factor: 5.182

9.  Correlation between Helicobacter pylori Infection and Metabolic Abnormality in General Population: A Cross-Sectional Study.

Authors:  Li-Juan Lu; Ning-Bo Hao; Jian-Jun Liu; Xue Li; Rui-Ling Wang
Journal:  Gastroenterol Res Pract       Date:  2018-03-20       Impact factor: 2.260

10.  Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome.

Authors:  Chen Chen; Caiyun Zhang; Xuelin Wang; Feijuan Zhang; Ze Zhang; Pengchai Ma; Shuzhi Feng
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-07       Impact factor: 2.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.